Cargando…

Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis

BACKGROUND: Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions. Cytokines play important roles in facilitating the immune response and augmenting the pathogenic antibody production. The current study aims to sensitively characterize the serum levels of cytokines with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huan, Xiao, Zhao, Rui, Song, Jie, Zhong, Huahua, Su, Manqiqige, Yan, Chong, Wang, Ying, Chen, Sheng, Zhou, Zhirui, Lu, Jiahong, Xi, Jianying, Luo, Sushan, Zhao, Chongbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145157/ https://www.ncbi.nlm.nih.gov/pubmed/35624411 http://dx.doi.org/10.1186/s12865-022-00501-8

Ejemplares similares

Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis
por: Zhao, Rui, et al.
Publicado: (2021)

Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs
por: Cetin, Hakan, et al.
Publicado: (2020)

Pneumonia in myasthenia gravis: Microbial etiology and clinical management
por: Su, Manqiqige, et al.
Publicado: (2022)

Herpesvirus entry mediator on T cells as a protective factor for myasthenia gravis: A Mendelian randomization study
por: Zhong, Huahua, et al.
Publicado: (2022)

Risk factors for pregnancy-related clinical outcome in myasthenia gravis: a systemic review and meta-analysis
por: Su, Manqiqige, et al.
Publicado: (2022)

A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis
por: Cai, Yu, et al.
Publicado: (2021)

Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients
por: Kordas, Gregory, et al.
Publicado: (2014)

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK
por: Yilmaz, Vuslat, et al.
Publicado: (2015)

Compromised fidelity of B‐cell tolerance checkpoints in AChR and MuSK myasthenia gravis
por: Lee, Jae‐Yun, et al.
Publicado: (2016)

Plasma Myokine Profiles in Patients With AChR- and MuSK-Ab-Positive Myasthenia Gravis
por: Seok, Jo Woon, et al.
Publicado: (2023)

The Clinical Outcome in AChR-Positive Generalized Myasthenia Gravis: A Retrospective Observational Study
por: Ojha, Pawan T., et al.
Publicado: (2023)

Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis
por: Bastakoti, Sanjiv, et al.
Publicado: (2021)

Correction: Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients
Publicado: (2015)

Correction: Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients
Publicado: (2015)

Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient
por: Saxena, Abhishek, et al.
Publicado: (2017)

SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody
por: Huda, Saif, et al.
Publicado: (2019)

Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort
por: Lupica, Antonino, et al.
Publicado: (2022)

Oral Microbiota Profile in a Group of Anti-AChR Antibody–Positive Myasthenia Gravis Patients
por: Huang, Chao, et al.
Publicado: (2022)

IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis
por: Maurer, Marie, et al.
Publicado: (2015)

Autoantibody of NRIP, a novel AChR‐interacting protein, plays a detrimental role in myasthenia gravis
por: Tsai, Li‐Kai, et al.
Publicado: (2021)

Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis
por: Spagni, Gregorio, et al.
Publicado: (2022)

Clinical Outcomes in AchR Antibody-Positive Myasthenia Gravis: Where Does Rituximab Stand in the Current Times?
por: Dhamne, Megha Chetan
Publicado: (2023)

Increased Frequency of Myeloid-Derived Suppressor Cells in Myasthenia Gravis After Immunotherapy
por: Wang, Yan, et al.
Publicado: (2022)

Caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate dendric cell IL-1-IL-17 pathway
por: Wang, Cong-Cong, et al.
Publicado: (2015)

The Association of PTPN22 R620W Polymorphism Is Stronger with Late-Onset AChR-Myasthenia Gravis in Turkey
por: Kaya, Gizem A., et al.
Publicado: (2014)

CD4(+) T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS
por: Çebi, Merve, et al.
Publicado: (2020)

Clinical Characteristics and Prognosis of Anti-AChR Positive Myasthenia Gravis Combined With Anti-LRP4 or Anti-Titin Antibody
por: Chen, Yuping, et al.
Publicado: (2022)

Comorbid Autoimmune Diseases in Patients With Myasthenia Gravis: A Retrospective Cross-Sectional Study of a Chinese Cohort
por: Shi, Jianquan, et al.
Publicado: (2021)

Short-term outcome prediction for myasthenia gravis: an explainable machine learning model
por: Zhong, Huahua, et al.
Publicado: (2023)

Peripheral immune landscape for hypercytokinemia in myasthenic crisis utilizing single-cell transcriptomics
por: Zhong, Huahua, et al.
Publicado: (2023)

IL-4Rα Polymorphism Is Associated With Myasthenia Gravis in Chinese Han Population
por: Jiang, Ping, et al.
Publicado: (2018)

FoxP3(−) Tr1 Cell in Generalized Myasthenia Gravis and Its Relationship With the Anti-AChR Antibody and Immunomodulatory Cytokines
por: Meng, Huanyu, et al.
Publicado: (2021)

Juvenile Generalized Myasthenia Gravis With AChR and MuSK Antibody Double Positivity: A Case Report With a Review of the Literature
por: Ge, XiuShan, et al.
Publicado: (2022)

Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review
por: Waheed, Waqar, et al.
Publicado: (2022)

Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients
por: Lekova, Eleonora, et al.
Publicado: (2022)

A Targeted Complement Inhibitor CRIg/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats via Immune Modulation
por: Song, Jie, et al.
Publicado: (2022)

Myasthenia Gravis With Thymoma, Manifesting as AChR-Ab-Positive, Distinct Bulbar Palsy Accompanied by Dysgeusia: A Case Series and Review of Literature
por: Zhu, Kai, et al.
Publicado: (2018)

A Patient with Fulminant Myasthenia Gravis Is Seropositive for Both AChR and LRP4 Antibodies, Complicated by Autoimmune Polyglandular Syndrome Type 3
por: Inoue, Hiroyasu, et al.
Publicado: (2020)

Effective Early Treatment of AChR Antibody-Positive Myasthenia Gravis with Rituximab; the Experience from a Neuroimmunology Clinic in a Developing Country
por: Mathew, Thomas, et al.
Publicado: (2021)

Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review [Erratum]
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t9ldq9487ue60jda0vonjj4oop